Publication Name	World Journal of Methodology
Manuscript ID	7364
Country	Italy

Received	2013-11-15 15:00
Peer-Review Started	2013-11-16 15:27
To Make the First Decision	2013-12-25 18:05
Return for Revision	2013-12-31 15:12
Revised	2014-01-19 16:03
Second Decision	2014-03-18 15:02
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-03-18 15:25
Articles in Press	2014-05-23 12:27
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-03-31 01:11
Typeset the Manuscript	2014-07-08 20:37
Publish the Manuscript Online	2014-08-20 20:59

ISSN	2222-0682 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Systematic Reviews
Article Title	End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review
Manuscript Source	Invited Manuscript
All Author List	Giuseppe Colloca, Antonella Venturino and Ilaria Governato
Funding Agency and Grant Number
Corresponding Author	Dr. Giuseppe Colloca, MD, Division of Medical Oncology, “Giovanni Borea” Hospital, Via Giovanni Borea 56, I-18038 Sanremo, Italy. g.colloca@katamail.com
Key Words	Metastatic castration-resistant prostate cancer; End points; Progression-free survival; Prostate-specific antigen; Chemotherapy; Palliative response
Core Tip	The approval in the last decade of new drugs that have increased survival of patients with metastatic castration-resistant prostate cancer (mCRPC) has weakened the role of overall survival (OS) as end point. The prevailing bone-only spread of mCRPC severely limits disease evaluation using the standard criteria of conventional radiology. On the other hand, recent retrospective analyses of prostate-specific antigen response after chemotherapy did not support this measure as a surrogate end point of OS. This lack of reliable surrogate end points is a problem for the conduction of phase Ⅱ studies which test the activity of new drugs.
Publish Date	2014-08-20 20:59
Citation	Colloca G, Venturino A, Governato I. End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review. World J Methodol 2014; 4(2): 123-132
URL	http://www.wjgnet.com/2222-0682/full/v4/i2/123.htm
DOI	http://dx.doi.org/10.5662/wjm.v4.i2.123

Full Article (PDF)	WJM-4-123.pdf
Full Article (Word)	WJM-4-123.doc
Manuscript File	7364-Review.doc
Answering Reviewers	7364-Answering reviewers.pdf
Copyright License Agreement	7364-Copyright assignment.pdf
Peer-review Report	7364-Peer reviews.pdf
Scientific Editor Work List	7364-Scientific editor work list.doc